Evidence map›Paper›PMID 40520982›Full record

ReviewJAACAP open2025

Review: Child Psychiatry in the Era of Genomics: The Promise of Translational Genetics Research for the Clinic.

Sarah E Fitzpatrick, Irene Antony, Erika L Nurmi, Thomas V Fernandez, Wendy K Chung, Catherine A Brownstein, Joseph Gonzalez-Heydrich, Raquel E Gur, Amanda R Merner, Gabriel Lázaro-Muñoz and 3 more

Abstract readReview
In one paragraph

Review in JAACAP open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genetic PolymorphismsPharmaceuticals (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sarah E FitzpatrickYale School of Medicine, New Haven, Connecticut.
Irene AntonyHarvard Medical School, Boston, Massachusetts.
Erika L NurmiUniversity of California, Los Angeles, Los Angeles, California.
Thomas V FernandezYale School of Medicine, New Haven, Connecticut.
Wendy K ChungHarvard Medical School, Boston, Massachusetts.
Catherine A BrownsteinHarvard Medical School, Boston, Massachusetts.
Joseph Gonzalez-HeydrichHarvard Medical School, Boston, Massachusetts.
Raquel E GurPenn Medicine-Children's Hospital of Philadelphia Lifespan Brain Institute, Philadelphia, Pennsylvania.
Amanda R MernerHarvard Medical School, Boston, Massachusetts.
Gabriel Lázaro-MuñozHarvard Medical School, Boston, Massachusetts.
Matthew W StateUniversity of California, San Francisco, San Francisco, California.
Kevin M SimonHarvard Medical School, Boston, Massachusetts.
Ellen J HoffmanYale School of Medicine, New Haven, Connecticut.

Funding

Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
Genetic Architecture of Early-Onset Psychosis in Mexicans (EPIMex)R01MH133621 · NIMH · BOSTON CHILDREN'S HOSPITAL · PI Laura A. Almasy, Carlos Daniel Bustamante · 2023 to 2026
$9.5M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
2/7-Collaborative genomic studies of Tourette DisorderR01MH115963 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STATE, MATTHEW W. · 2018 to 2022
$4.9M
High-throughput Functional Analysis of Autism Risk GenesR01MH116002 · NIMH · YALE UNIVERSITY · PI ELLEN J HOFFMAN · 2018 to 2026
$4.5M
Research Training for Medical Students & Physician-Scientists in Child PsychiatryR25MH077823 · NIMH · YALE UNIVERSITY · PI ANDRES S MARTIN · 2006 to 2026
$4.0M
Evolution of Psychosis in Youth: Multimodal Risk and Resilience MarkersR01MH119219 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E, GUR, RUBEN C. · 2019 to 2023
$3.8M
1/9: Dissecting the effects of genomic variants on nenriched for neuropsychiatric disorderseurobehavioral dimensions in CNVs U01MH119738 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI GUR, RAQUEL E · 2019 to 2023
$3.2M
Neurogenetic Investigations of Obsessive-Compulsive DisorderR01MH114927 · NIMH · YALE UNIVERSITY · PI FERNANDEZ, THOMAS V · 2018 to 2022
$2.8M
Polygenic Risk Scores in Child and Adolescent Psychiatry: Ethical, Clinical, and Legal ImplicationsR01MH128676 · NIMH · BAYLOR COLLEGE OF MEDICINE · PI LAZARO-MUNOZ, GABRIEL, PEREIRA, STACEY · 2021 to 2024
$2.5M
Investigating the Translatome in Genetic Models of AutismR21MH133245 · NIMH · YALE UNIVERSITY · PI HOFFMAN, ELLEN J · 2023 to 2024
$459k
The Role of the ASD Risk Gene CHD8 in Neural DevelopmentF30MH132282 · NIMH · YALE UNIVERSITY · PI FITZPATRICK, SARAH E. · 2022 to 2025
$153k
NICHD NIH HHS P50 HD105351NIGMS NIH HHS T32 GM144273NIMH NIH HHS F30 MH132282NIMH NIH HHS R01 MH114927NIMH NIH HHS R01 MH115963NIMH NIH HHS R01 MH116002NIMH NIH HHS R01 MH119219NIMH NIH HHS R01 MH128676NIMH NIH HHS R01 MH133621NIMH NIH HHS R21 MH133245NIMH NIH HHS R25 MH077823NIMH NIH HHS U01 MH119738
6 · The paper itself

Abstract

Objective: There has been remarkable progress in recent years in understanding the genetic underpinnings of child psychiatric disorders. Concurrently, genetic testing is becoming increasingly available in the clinic. However, many clinicians report a lack of familiarity with genetics and how genetic testing might inform a clinical evaluation. This review aims to introduce clinicians to cutting-edge research in child psychiatric genetics and discuss the emerging role of genetic tests in clinical practice. Method: This review highlights major findings presented at the Research Institute of the 69th American Academy of Child and Adolescent Psychiatry Annual Meeting. Results: An overview of critical genetic concepts for clinicians is provided along with a discussion of recent advances in child psychiatric genetics, focusing on autism spectrum disorder, where whole exome sequencing has led to the identification of approximately 250 high-confidence risk genes. The review describes how similar approaches to gene discovery are beginning to shed light on the genetic architecture of early-onset psychosis, Tourette's disorder, obsessive-compulsive disorder, and other disorders. In addition, the practical limitations of pharmacogenetic testing, ethical considerations, and barriers to clinical genetic testing are discussed. Finally, the promise of genetic research for advancing understanding of the pathophysiology of these disorders is illustrated. Conclusion: This review aims to improve clinicians' knowledge of how genetic findings might inform clinical evaluation and management of child psychiatric disorders and the potential for groundbreaking research in the field to shape the development of new treatments. Diversity & Inclusion Statement: One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented racial and/or ethnic groups in science. We actively worked to promote sex and gender balance in our author group.

Indexed as

autism spectrum disorderchild psychiatrygeneticsgenomicspharmacogenetics

Identifiers

PMID40520982
PMCPMC12166933

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.